Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
61 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India |
| not yet recruiting |
| Phase 4 |
| 30 |
| Eli Lilly and CompanyINDUSTRY |
| 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | active not recruiting | Phase 4 | 134 | Novartis PharmaceuticalsINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT06429761 | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients(STRIDE) | active not recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06862219 | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | recruiting | Phase 4 | 100 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT07459543 | A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India | not yet recruiting | Phase 4 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05631795 | Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment(ALPINIST) | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06427811 | Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation(ASC4INDIA) | completed | Phase 4 | 85 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03934684 | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | completed | Phase 4 | 101 | AmgenINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03573960 | A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer | completed | Phase 4 | 50 | Eisai Pharmaceuticals India Pvt. LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India | recruiting | Phase 4 | 124 | TakedaINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT02625389 | A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures | completed | Phase 4 | 132 | GuerbetINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT01496313 | To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | completed | Phase 4 | 81 | SanofiINDUSTRY | 9 | Oct 3, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04513522 | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India(CheckMate 7C9) | completed | Phase 4 | 101 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT01932125 | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | completed | Phase 4 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04362072 | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer | completed | Phase 4 | 71 | PfizerINDUSTRY | 7 | Jun 11, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT04330040 | Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer(SOLI) | completed | Phase 4 | 202 | AstraZenecaINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03564938 | Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). | completed | Phase 4 | 100 | BayerINDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04930536 | Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma | completed | Phase 4 | 103 | AstraZenecaINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04707196 | A Study of Abemaciclib in Indian Women With Advanced Breast Cancer | completed | Phase 4 | 200 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03677596 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | completed | Phase 4 | 102 | PfizerINDUSTRY | 8 | Nov 22, 2023 | clinicaltrials |
| NCT04297254 | A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | completed | Phase 4 | 50 | Eisai Pharmaceuticals India Pvt. LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT00923702 | Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India | unknown | Phase 4 | 22,729 | Partha BasuOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT02419742 | Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen | completed | Phase 4 | 110 | Hoffmann-La RocheINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02679755 | Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer | completed | Phase 4 | 252 | PfizerINDUSTRY | 2 | Jul 27, 2022 | clinicaltrials |
| NCT02726009 | A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer | completed | Phase 4 | 230 | Ferring PharmaceuticalsINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT03511378 | Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer | completed | Phase 4 | 138 | Lupin Ltd.INDUSTRY | 1 | Jun 15, 2021 | clinicaltrials |
| NCT03853551 | Osimertinib Study in Indian Patients | completed | Phase 4 | 60 | AstraZenecaINDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03444766 | Study of Nivolumab for Advanced Cancers in India | completed | Phase 4 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT01031069 | Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females | completed | Phase 4 | 873 | GlaxoSmithKlineINDUSTRY | 4 | Jul 21, 2020 | clinicaltrials |
| NCT02301962 | Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer | unknown | Phase 4 | 58 | Dr. Reddy's Laboratories LimitedINDUSTRY | 1 | Dec 16, 2019 | clinicaltrials |
| NCT03583944 | A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | completed | Phase 4 | 200 | Eisai Inc.INDUSTRY | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02445586 | Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer | completed | Phase 4 | 52 | Hoffmann-La RocheINDUSTRY | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01525550 | A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 4 | 106 | PfizerINDUSTRY | 15 | Jul 30, 2019 | clinicaltrials |
| NCT01206764 | A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. | completed | Phase 4 | 143 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 24, 2019 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials